Vectura sinks after PhIII asthma trial ends in failure, marking another setback
Vectura has opted to ax its most advanced, wholly owned therapy after it failed a pivotal Phase III study for asthma.
Researchers used a nebulizer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
